These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 22488148)

  • 1. In vivo assessment of antimicrobial activity and toxicity of repeated 1% povidone-iodine applications vs a single 5% povidone-iodine application.
    Teren D; Neuman G; Abulafia A; Gelman E; Assayag E; Hajj A; Shwartz O; Zadok D
    J Cataract Refract Surg; 2024 Jul; 50(7):682-687. PubMed ID: 38477800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Antibiotic Therapy in the Ocular Environment: The Benefits of Using Moxifloxacin Eyedrops.
    Drago L
    Microorganisms; 2024 Mar; 12(4):. PubMed ID: 38674593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contact lenses in dry eye disease and associated ocular surface disorders.
    Chaudhary S; Ghimire D; Basu S; Agrawal V; Jacobs DS; Shanbhag SS
    Indian J Ophthalmol; 2023 Apr; 71(4):1142-1153. PubMed ID: 37026246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keratoprosthesis prophylaxis: is it time for a paradigm shift?
    Pelletier JS; Barone SB; Capriotii JA
    Clin Ophthalmol; 2018; 12():1785-1788. PubMed ID: 30254417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungal keratitis and endophthalmitis after implantation of type 1 keratoprosthesis.
    Malhotra C; Jain AK; Aggarwal N
    Oman J Ophthalmol; 2018; 11(1):62-64. PubMed ID: 29563700
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Al-Otaibi HM; Talea M; Kirat O; Stone DU; May WN; Kozak I
    Middle East Afr J Ophthalmol; 2016; 23(4):329-331. PubMed ID: 27994401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Concepts in the Management of Unique Post-keratoplasty Infections.
    Schallhorn JM; Rose-Nussbaumer J
    Curr Ophthalmol Rep; 2015 Sep; 3(3):184-191. PubMed ID: 26618075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fungal Infections After Boston Type 1 Keratoprosthesis Implantation: Literature Review and In Vitro Antifungal Activity of Hypochlorous Acid.
    Odorcic S; Haas W; Gilmore MS; Dohlman CH
    Cornea; 2015 Dec; 34(12):1599-605. PubMed ID: 26488624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic Vancomycin Drops Reduce the Severity of Early Bacterial Keratitis in Keratoprosthesis.
    Konstantopoulos A; Tan XW; Goh GT; Saraswathi P; Chen L; Nyein CL; Zhou L; Beuerman R; Tan DT; Mehta JS
    PLoS One; 2015; 10(10):e0139653. PubMed ID: 26460791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    Am J Ophthalmol; 2004 Jul; 138(1):33-7. PubMed ID: 15234279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of povidone-iodine in ophthalmology.
    Grzybowski A; Kanclerz P; Myers WG
    Curr Opin Ophthalmol; 2018 Jan; 29(1):19-32. PubMed ID: 28984794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of endophthalmitis following Boston keratoprosthesis type 1.
    Robert MC; Moussally K; Harissi-Dagher M
    Br J Ophthalmol; 2012 Jun; 96(6):776-80. PubMed ID: 22493035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiota evaluation of patients with a Boston type I keratoprosthesis treated with topical 0.5% moxifloxacin and 5% povidone-iodine.
    Magalhães FP; do Nascimento HM; Ecker DJ; Sannes-Lowery KA; Sampath R; Rosenblatt MI; de Sousa LB; de Oliveira LA
    Cornea; 2013 Apr; 32(4):407-11. PubMed ID: 22488148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac.
    Halachmi-Eyal O; Lang Y; Keness Y; Miron D
    J Cataract Refract Surg; 2009 Dec; 35(12):2109-14. PubMed ID: 19969216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery.
    Bucci FA; Amico LM; Evans RE
    Eye Contact Lens; 2008 Jan; 34(1):39-42. PubMed ID: 18180682
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.